Linagliptin Stada

Linagliptin, the active ingredient in Linagliptin Stada, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for adult use. It is employed to improve blood glucose control in patients with type 2 diabetes mellitus. It is indicated for adult patients who require additional glycemic control when diet and exercise alone are insufficient.

GNH USA supplies Linagliptin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions.

Linagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus.

Type 2 diabetes mellitus (monotherapy): lowers HbA1c and fasting glucose levels when used alone. Type 2 diabetes mellitus (combination with metformin): enhances overall glycemic control by adding a complementary mechanism. Type 2 diabetes mellitus (adjunct to diet and exercise): supports blood sugar regulation as part of comprehensive lifestyle management.

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient head pain. - Dizziness: sensation of light‑headedness. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Bullous pemphigoid or Stevens‑Johnson syndrome: serious skin disorders requiring immediate medical attention.

When prescribing Linagliptin, clinicians should consider several safety aspects to minimize risk.

Renal impairment: monitor renal function, although dose adjustment is not routinely required. Hepatic impairment: use with caution and observe liver enzymes. Cardiovascular disease: assess for any history of heart failure or ischemic events. Pregnancy and lactation: safety has not been established; avoid use unless benefits outweigh risks. Elderly patients: watch for hypoglycemia, especially when combined with insulin or sulfonylureas. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Linagliptin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant use with insulin or sulfonylureas: may cause severe hypoglycemia. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): can reduce linagliptin exposure and diminish glucose‑lowering effect. - Combination with other DPP‑4 inhibitors: additive effect increases risk of adverse events.

Moderate Interactions (Monitor Closely): - Diuretics (thiazides, loop diuretics): may enhance the risk of dehydration and affect blood glucose. - ACE inhibitors or ARBs: monitor blood pressure and renal function. - NSAIDs: observe for potential renal function changes. - Anticoagulants (warfarin): watch for altered INR values.